Search research articles
Contact Us
Filters
Showing results (41-50 of 188) with videos related to
Page
of 19
Sort By:
The Oncologist
|
July 9, 2025
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors
John D Powderly, Martin E Gutierrez, Ani S Balmanoukian, et al.
Transplantation and Cellular Therapy
|
March 15, 2025
Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products
Justin J Lievense, Cynthia Nijenhuis, Inge Jedema, et al.
Japanese Journal of Clinical Oncology
|
February 22, 2020
Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data
Christopher J D Wallis, Keith Lawson, Mohit Butaney, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
Harriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
Jeffrey Weber, John A Thompson, Omid Hamid, et al.
Cancer Immunity
|
July 9, 2013
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma
Jeffrey Weber, Omid Hamid, Asim Amin, et al.
Journal for Immunotherapy of Cancer
|
February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
Allison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
Journal of Translational Medicine
|
November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid, Henrik Schmidt, Aviram Nissan, et al.
Journal of the American Academy of Dermatology
|
January 20, 2020
Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma
Anthony T Nguyen, Michael Luu, Diana J Lu, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2019
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018
Paolo A Ascierto, Lisa H Butterfield, Sandra Demaria, et al.
Page
of 19
Search research articles
Search
Showing results (41-50 of 188) with videos related to
Sort By:
Page
of 19
The Oncologist
|
July 9, 2025
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors
John D Powderly, Martin E Gutierrez, Ani S Balmanoukian, et al.
Transplantation and Cellular Therapy
|
March 15, 2025
Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products
Justin J Lievense, Cynthia Nijenhuis, Inge Jedema, et al.
Japanese Journal of Clinical Oncology
|
February 22, 2020
Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data
Christopher J D Wallis, Keith Lawson, Mohit Butaney, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
Harriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
Jeffrey Weber, John A Thompson, Omid Hamid, et al.
Cancer Immunity
|
July 9, 2013
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma
Jeffrey Weber, Omid Hamid, Asim Amin, et al.
Journal for Immunotherapy of Cancer
|
February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
Allison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
Journal of Translational Medicine
|
November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid, Henrik Schmidt, Aviram Nissan, et al.
Journal of the American Academy of Dermatology
|
January 20, 2020
Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma
Anthony T Nguyen, Michael Luu, Diana J Lu, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2019
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018
Paolo A Ascierto, Lisa H Butterfield, Sandra Demaria, et al.
Page
of 19